/MTEM
Molecular Templates, Inc.
MTEM • OTCMTEM • OTC • Healthcare
$0.00-0.00%-0.00
$0.00-0.00%(-0.00)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
70Bullish
Risk
59Moderate
Momentum
20Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
87.9%▲27.4pp
Revenue after COGS
Operating
-18.3%▲431.6pp
After operating expenses
Net
-14.2%▲455.2pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-0.1
Price vs earnings
EV/EBITDA
1.6
Enterprise value
FCF Yield
-3754.3%
Cash generation
Earnings Yield
-725.8%
Inverse of P/E
Capital Efficiency
-88
GoAI Quality ScorePoor
ROEReturn on Equity
-192.9%Weak
ROAReturn on Assets
-23.0%Weak
ROICReturn on Invested Capital
-50.9%Weak
Financial Health
Current RatioWeak
0.97
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
0.61x
Debt repayment capacity (<3x)
Income QualityStrong
5.15
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $57.31M | $19.75M | $38.70M | $18.84M | $22.27M |
| Gross Profit | $50.40M | $11.95M | $32.00M | -$74.12M | -$28.25M |
| Gross Margin | 87.9% | 60.5% | 82.7% | -393.3% | -126.8% |
| Operating Income | -$10.47M | -$88.87M | -$80.07M | -$100.84M | -$70.45M |
| Net Income | -$8.12M | -$92.72M | -$83.01M | -$104.92M | -$69.42M |
| Net Margin | -14.2% | -469.4% | -214.5% | -556.7% | -311.7% |
| EPS | -$1.80 | -$24.75 | -$22.50 | -$33.06 | -$27.62 |
Rating Distribution
Strong Buy
0
0%
Buy
6
75%
Hold
1
13%
Sell
1
13%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Barclays● Maintain
Overweight
2022-11-11Barclays● Maintain
Overweight
2022-11-10B of A Securities▼ Downgrade
Buy→Underperform
2022-05-27B of A Securities▼ Downgrade
Buy→Underperform
2022-05-26Barclays● Maintain
Overweight
2022-03-30Barclays● Maintain
Overweight
2022-03-29B of A Securities● Maintain
Buy
2021-04-21UBS● Maintain
Neutral
2021-02-01Jefferies● Maintain
Buy
2020-09-08Oppenheimer● Maintain
Outperform
2020-05-12Earnings History & Surprises
BEAT RATE
56%
Last 16 quarters
AVG SURPRISE
-11.7%
EPS vs Estimate
BEATS / MISSES
9/6
1 met exactly
LATEST EPS
$-1.23
Q3 '24
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q3 '24
+14.6%
$-1.23 vs $-1.44
Q2 '24
+110.3%
$0.08 vs $-0.78
Q1 '24
+65.2%
$-0.73 vs $-2.10
Q4 '23
+69.6%
$-0.82 vs $-2.70
Q3 '23
+37.1%
$-3.30 vs $-5.25
Q1 '23
-56.0%
$-5.85 vs $-3.75
Q1 '23
+40.0%
$-0.18 vs $-0.30
Q4 '22
+8.3%
$-6.60 vs $-7.20
Q3 '22
-2.3%
$-6.60 vs $-6.45
Q2 '22
+9.5%
$-5.70 vs $-6.30
Q1 '22
$-2.70 vs $-2.70
Q4 '21
-68.8%
$-8.10 vs $-4.80
No investor questions available.
Latest News
No news available